Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
Keyword(s):
2018 ◽
Vol 119
(9)
◽
pp. 1075-1085
◽
Keyword(s):
2014 ◽
Vol 69
(10)
◽
pp. 594-596
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. 5501-5501
◽
Keyword(s):
2016 ◽
Vol 115
(11)
◽
pp. 1313-1320
◽
Keyword(s):
2018 ◽
Keyword(s):